Market Scenario: The Asia Pacific Insomnia Market is anticipated to reach USD 272.68 Million by 2030 at 6.90% CAGR during the forecast period 2022-2030.Insomnia is the most common sleep disorder. It involves disturbance in the sleep or trouble in falling asleep or waking up too early in the morning. The exact cause is still a mystery. Insomnia can be exist alone or conjugated with the other psychiatric problems. It is most common is women and mostly occur in young age. Conditions like pregnancy, postpartum and menopause can increase the severity of insomnia in the patients. Asia Pacific insomnia market is driven by increasing number of the number of patients suffering from sleep disorders due to adoption of alcohol, caffeine and tobacco by a huge number of population. Many research has explain that psychological and behavioural factor are responsible for causing insomnia. Increasing workload and stressful modern life has increase the demand for the sleeping pills. Technological development and increasing healthcare expenditure has also contributed in the growth of the market. Increasing prevalence of diseases like Alzheimer’s and Parkinson’s has also anticipated to be factor for the growth of this market across Asia Pacific. On other hand, lack of education and lack of awareness may restrain the growth of the market. Study Objectives Asia Pacific Insomnia Market Research Report
Figure 1- Asia Pacific Insomnia Market, by types of therapy
Key Players for Asia Pacific Insomnia market Takeda Pharmaceutical Company (Japan), Pfizer, Inc. (US), Eisai, Co. (Japan), Merck & Co Inc (US), Sanofi (France), GlaxoSmithKline Plc. (UK), Meda Consumer Healthcare Inc (US), Care Fusion Corporation (US), Pernix Therapeutics (US), Purdue Pharma L.P. (US), Consumer Healthcare Inc. (Canada), Dainippon Sumitomo (Japan), ECR Pharmaceuticals (US), Johnson & Johnson (US), Astellas (UK), Biocodex S A (France), Neurim (Switzerland), Flynn Pharma (UK). Segmentation Asia Pacific insomnia market has been segmented on the basis of types of therapy which comprises pharmacological therapy and non-pharmacological therapy. Pharmacological therapy is further segmented into benzodiazepines, non-benzodiazepines, melatonin receptor agonists and other. Non pharmacological treatment are further segmented into relaxation therapy, cognitive behavioural therapy, sleep hygiene education, stimulus control, paradoxical intention and other. By drug formulation they are segmented as capsules, tablet and others. On the basis of type of disease they are poor quality of sleep, sleep maintenance and other.
Regional Analysis On regional basis, Japan accounts the largest share in the Asia Pacific insomnia market. 1 in every 5 people in japan is suffering from acute or chronic symptoms of insomnia. In Japan insomnia is the major problem than anxiety and depression. India and China are also contribute major share in the market. Approximately 5% of total India’s population is suffering from insomnia. This increasing number of people suffering from insomnia is the major driving factor for the market in Asia Pacific region.
The report for Asia Pacific insomnia market research report of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions. Intended Audience